Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-137 in healthy Japanese male subjects
NCT02322606Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Nov 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-137 in schizophrenia, sponsored by Takeda. Planned start Nov 2014; status: withdrawn.
02
Drugs
TAK-137
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02322606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322606.